title: The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
abstract: METHODS
  A total of 102 patients were randomized to either mono-therapy with simvastatin (40 mg daily) or triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively.
  
  
  RESULTS
  Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity (p = 0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy (p = 0.01).
  
  
  CONCLUSIONS
  No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes.
  
  
  BACKGROUND
  NCT00687076; Link: http://clinicaltrials.gov/ct2/show/NCT00687076.
authors.affiliation: Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: gbrunner@bcm.edu.
authors.forename: Gerd
authors.initials: G
authors.lastname: Brunner
authors.forename: Eric Y
authors.initials: EY
authors.lastname: Yang
authors.forename: Anirudh
authors.initials: A
authors.lastname: Kumar
authors.forename: Wensheng
authors.initials: W
authors.lastname: Sun
authors.forename: Salim S
authors.initials: SS
authors.lastname: Virani
authors.forename: Smita I
authors.initials: SI
authors.lastname: Negi
authors.forename: Tyler
authors.initials: T
authors.lastname: Murray
authors.forename: Peter H
authors.initials: PH
authors.lastname: Lin
authors.forename: Ron C
authors.initials: RC
authors.lastname: Hoogeveen
authors.forename: Changyi
authors.initials: C
authors.lastname: Chen
authors.forename: Jing-Fei
authors.initials: JF
authors.lastname: Dong
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Kougias
authors.forename: Addison
authors.initials: A
authors.lastname: Taylor
authors.forename: Alan B
authors.initials: AB
authors.lastname: Lumsden
authors.forename: Vijay
authors.initials: V
authors.lastname: Nambi
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: Joel D
authors.initials: JD
authors.lastname: Morrisett
mesh_terms: D000368:Aged; D001384:Azetidines / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects; D000069438:Ezetimibe; D005260:Female; D005263:Femoral Artery / Q000473:pathology; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000008:administration & dosage; D058729:Peripheral Arterial Disease / Q000097:blood*; D019821:Simvastatin / Q000008:administration & dosage
chemical_list: D001384:Azetidines; D008055:Lipids; D008074:Lipoproteins; D009525:Niacin; D002784:Cholesterol; D019821:Simvastatin; D000069438:Ezetimibe
keywords: ABI; Atherosclerosis; ICC; Lipids; MRI; Magnetic resonance imaging; PAD; PDW; Peripheral artery disease; Proton-density-weighted; SFA; T1-weighted; T1W; T2-weighted; T2W; ankle brachial index; intra-class correlation; magnetic resonance imaging; peripheral artery disease; superficial femoral artery